Kami Maddocks, MD
Ohio State University Comprehensive Cancer Center · Ohio State University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kami Maddocks, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:54 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03583424 · Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaOhio State University Comprehensive Cancer Center · completed · Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma · principal investigator
- Ph2NCT03478514 · Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaAlliance Foundation Trials, LLC. · active not recruiting · Mantle Cell Lymphoma, B Cell Lymphoma · study chair
- Ph1NCT02950220 · Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaKami Maddocks · completed · B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma · principal investigator
- Ph1NCT02049541 · Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaKami Maddocks, MD · completed · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma · principal investigator
- Ph2NCT01589302 · PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic LeukemiaKami Maddocks, MD · active not recruiting · Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT01479842 · Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaKami Maddocks, MD · active not recruiting · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Shared Resource 10: Pharmacoanalytical Shared Resource (PhASR)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Mitch A Phelps · fiscal years 2013 to 2026Named on NCT02950220
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.